



<http://www.endocyte.com>

July 14, 2009

**NEWS RELEASE**

**Endocyte to present data on EC145 at the IASLC 13<sup>th</sup> World Conference on Lung Cancer**

WEST LAFAYETTE, Ind. – July 14, 2009 –Endocyte, Inc., a cancer drug discovery and development company, today announced that it would report results of a Phase II clinical study of EC145 in patients with advanced lung cancer. The data will be presented as part of the 13th World Conference on Lung Cancer to be held July 31 to August 4, 2009, in San Francisco.

Dr. Martin Edelman, of the Greenebaum Cancer Center, University of Maryland, principle investigator of the study, will present the data during a session entitled “Catch and Release: Intracellularly activated Chemotherapy” on Saturday, August 1 from 2:30 - 4:00 p.m. in the Moscone Center West, Rooms 3020-3022, Level 3, PD 3.4.4.

**About Endocyte**

[Endocyte](#) is a privately-held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte’s advanced proprietary [Drug Guidance System](#) (DGS), the company is working to develop new drugs and diagnostic agents to treat many types of cancer and other serious diseases. The DGS platform makes it possible to use highly-potent drugs on extended and frequent dosing schedules and in combination with other drugs to maximize efficacy. The technology improves drug targeting and reduces the risk of side effects by combining drugs with ligands that are able to identify and attach to receptors found on tumor and other disease cells. Endocyte’s clinical development of EC20 and EC145 is progressing with the recent completion of accrual for the phase II trials in advanced ovarian and lung cancer. EC20 and EC145 are now being studied in an international randomized phase II trial of EC145 in combination with Doxil® for the treatment of women with platinum resistant ovarian cancer. Other clinical-stage products in the Endocyte pipeline include: EC0225, a targeted combination of two potent anticancer drugs; BMS753493, a potent drug being developed in partnership with Bristol-Myers Squibb; EC0489, a targeted cancer drug and EC17, a targeted immunotherapy agent. The company also has multiple product candidates in pre-clinical stage of development.

*This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise*

**Contact:**

Vickey Buskirk, media relations, Endocyte Inc., (765) 463-7175 ext. 1117, [vbuskirk@endocyte.com](mailto:vbuskirk@endocyte.com)